Reporting owner · CIK 0001410514
Kelly Thomas Patrick
Visual SEC Form 4 history across 1 companies, 1 transactions and 1 filings.
CFOChief Financial OfficerXenon Pharmaceuticals Inc.
Open-market mix
100%buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at Xenon Pharmaceuticals Inc. on Sep 30, 2026 valued at $559,740.
Review SEC filingLatest sale
No open-market insider sale is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
1 observations · Sep 30, 2026 – Sep 30, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 30, 202615,000 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 30, 2026 | 15,000 | Oct 1, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Sep 26
$559.7K
Transaction texture
Ownership and ticket size
Average P/S size$559.7K
Median P/S size$559.7K
Direct1
Indirect0
Sep 30, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
Kelly Thomas Patrick Insider Activity FAQ
SEC Form 4 context
Who is Kelly Thomas Patrick?
Kelly Thomas Patrick is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001410514.
Which companies has Kelly Thomas Patrick reported transactions for?
Xenon Pharmaceuticals Inc.
When was Kelly Thomas Patrick's latest insider buy?
buy at Xenon Pharmaceuticals Inc. on Sep 30, 2026 valued at $559,740.
When was Kelly Thomas Patrick's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.